VIDAZA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug VIDAZA contains one active pharmaceutical ingredient (API):

1	Azacitidine UNII M801H13NRU - AZACITIDINE
	Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA, RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways.
	Read more about Azacitidine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VIDAZA Powder for suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BC07	Azacitidine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	6100C, 6138C, 9597D, 9598E
BR	Câmara de Regulação do Mercado de Medicamentos	533200701159317
CA	Health Products and Food Branch	02336707
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	360160512
EE	Ravimiamet	1390968
ES	Centro de información online de medicamentos de la AEMPS	08488001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	170986
FR	Base de données publique des médicaments	61118337
GB	Medicines & Healthcare Products Regulatory Agency	152368
HK	Department of Health Drug Office	55407
IL	מִשְׂרַד הַבְּרִיאוּת	7338
JP	医薬品医療機器総合機構	4291419D1026
LT	Valstybinė vaistų kontrolės tarnyba	1035905
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	046M2013
NL	Z-Index G-Standaard, PRK	88692
NZ	Medicines and Medical Devices Safety Authority	13789
PL	Rejestru Produktów Leczniczych	100205420
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68131001
SG	Health Sciences Authority	13801P
TN	Direction de la Pharmacie et du Médicament	13483011H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699538774815
US	FDA, National Drug Code	59572-102
ZA	Health Products Regulatory Authority	A40/26/0521